6:03AM Amarin announces additional effects of Vascepa on lipoprotein particle concentration from the ANCHOR study presented at the National Lipid Association 2013 Annual Scientific Sessions (AMRN) 6.46 : Co presented additional data on Vascepa (icosapent ethyl) and its effect on lipoprotein particle concentration from the Phase 3 ANCHOR study at the National Lipid Association (NLA) 2013 Annual Scientific Session. The data presentation titled, "Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients with Persistent High Triglycerides (the ANCHOR Study)", reported that Vascepa 4 g/day, when added to optimized statin therapy for 12 weeks, significantly reduced median particle concentrations of total very-low-density lipoprotein (VLDL) by 12.2%, total low-density lipoprotein (LDL) by 7.7%, and small LDL particles by 13.5% across the 12 week treatment period, compared with placebo. Co also presented, or provided financial support for, research surrounding three additional topics at this year's NLA meeting, including:
pharmacokinetic data showing the lack of drug-drug interaction when Vascepa was administered with atorvastatin, a commonly prescribed cholesterol lowering medication
pharmacokinetic data showing the lack of drug-drug interaction when Vascepa was administered with warfarin, a commonly prescribed anticoagulant medication
eicosapentaenoic acid and its potential inhibition of the formation of membrane cholesterol crystalline domains
